Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

Experts stress that obesity is a disease, not a lifestyle choice, and call for better access to pharmacological and surgical ...

The pharmaceutical industry is not stopping there. There are already 100 new drug candidates in trials, all vying for a slice ...

This economic evaluation found that although tirzepatide and semaglutide offered substantial long-term health benefits, they were not ...

The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...